BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Prima Biomed (PRR.AX) to Present at the 37th Annual Deutsche Bank (DB) Health Care Conference


5/3/2012 8:47:22 AM

SYDNEY, AUSTRALIA--(Marketwire - May 03, 2012) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) announced today that Dr. Neil Frazer, Chief Medical Officer, will present at the Deutsche Health Care Conference on Tuesday, May 8, 2012 at 8:40am Eastern Time in Boston, MA. Dr. Frazer will provide an overview of the Company and its corporate activities.

The presentation will be webcast live and may be accessed by visiting Prima BioMed's website at http://www.primabiomed.com.au/investor/presentations.php. A replay of the webcast will be available for 10 business days following the presentation.

About Prima BioMed
Prima BioMed is a NASDAQ and ASX and listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology.

Prima's lead product is the CVac™ ovarian cancer therapy treatment. CVac™ has completed two successful clinical trials and is progressing advanced clinical development in the United States, Australia, and Europe.

The Company's broader, long term goal is to develop cancer treatment technologies and programs for global markets.


Contacts:
Dr. Neil Frazer
Chief Medical Officer
Prima BioMed
Ph: (919) 654 6736
E: Email Contact

US Investor Relations
Ms. Kathy Galante
Investor Relations
Burns McClellan, Inc
Ph: (212) 213-0006
E: Email Contact

Australia Investor / Media
James Moses
Investor and Media Relations
Mandate Corporate
Ph: +61 0 420 991 574
E: Email Contact


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->